Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.20.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Revenue:    
Contract research revenue $ 89,812 $ 119,750
Costs and Expenses:    
Research and development 11,234,548 6,787,474
General and administrative 7,776,300 7,978,821
Total costs and expenses 19,010,848 14,766,295
Loss from operations (18,921,036) (14,646,545)
Sale of New Jersey net operating loss 1,007,082
Other income, net 541,303 56,552
Benefit for income taxes 506,920
Net loss (17,372,651) (14,083,073)
Preferred stock series A accumulated dividends (338,613) (587,643)
Preferred stock series B accumulated dividends (585,547) (317,400)
Net loss attributable to common shareholders $ (18,296,811) $ (14,988,116)
Net loss attributable to common shareholders per share - basic and diluted $ (0.13) $ (0.15)
Weighted average common shares outstanding:    
Basic and diluted 145,195,196 98,103,210
Other comprehensive loss, net of tax    
Unrealized loss on securities available-for-sale $ (880)
Other comprehensive loss, net of tax (880)
Comprehensive loss attributable to shareholders $ (17,373,531) $ (14,083,073)